Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities research analysts at Wells Fargo ...

Axsome Therapeutics (AXSM – Research Report ... The potential regulatory approvals for AXS-07, AXS-14, and AXS-12 in the near to medium term, along with the expected submission of AXS-05 ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

17 analysts have expressed a variety of opinions on Axsome Therapeutics AXSM ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment ...

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...

Ratings for Axsome Therapeutics AXSM were provided ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit ...

Shares of Axsome Therapeutics (NASDAQ ... The settlement protects Axsome's exclusive rights over Auvelity for roughly 14 years -- a big win for Axsome. The resolution led Mizuho's Graig ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Axsome Therapeutics (AXSM) is climbing nearly 4% ... the FDA to accept AXSM's filing of its potential ADA treatment, AXS-05, for the agency's approval, and UBS anticipates that the drug will ...